DDInter286 DDInter899
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Caplacizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Turmeric
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Caplacizumab may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Caplacizumab may lead to a major life threatening interaction when taken with Prasugrel